PTK2 and non-small cell lung carcinoma: Taken together, our studies suggest that combined treatment with FAK and Hsp90 inhibitors synergistically inhibit the growth of NSCLC cells by abrogating the Akt/mTOR and Erk1⁄2 cell survival signaling, and activating caspase to induce cell death.